U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    46,650.86
    +196.52 (+0.42%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Novavax enters deal with New Zealand for 10.7M doses of COVID-19 vaccine candidate

  • Oops!
    Something went wrong.
    Please try again later.
Novavax enters deal with New Zealand for 10.7M doses of COVID-19 vaccine candidate
  • Oops!
    Something went wrong.
    Please try again later.

Dec 17 (Reuters) - Biotechnology company Novavax Inc said it had entered an agreement with the government of New Zealand for 10.7 million doses of its COVID-19 vaccine candidate.

"Under the terms of the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021", it said in a statement on Thursday.

The company will work with New Zealand's regulatory agency, Medsafe for approvals, it added.

The statement did not disclose further terms of the agreement. (Reporting by Kanishka Singh in Bengaluru; Editing by Himani Sarkar)